Burden of liver disease in the United States: Summary of a workshop
W. Ray Kim, Robert S. Brown, Norah A. Terrault, Hashem El‐Serag – 30 December 2003
Underexpression of mRNA in human hepatocellular carcinoma focusing on eight loci
Moritoshi Kinoshita, Masahiko Miyata – 30 December 2003 – Genetic alterations associated with human hepatocellular carcinoma (HCC) have been reported previously, but are not sufficient to specify differences of HCCs from precancerous diseases of the liver, such as hepatitis, hepatic fibrosis, and cirrhosis. In the present study, we performed differential gene display analysis (DGDA) to clarify the specific genetic alterations associated with gene expression changes in the course of development of HCC from chronic viral hepatitis.
Selective mitochondrial glutathione depletion by ethanol enhances acetaminophen toxicity in rat liver
Ping Zhao, Thomas F. Kalhorn, John T. Slattery – 30 December 2003 – Chronic alcohol consumption may potentiate acetaminophen (APAP) hepatotoxicity through enhanced formation of N‐acetyl‐p‐benzoquinone imine (NAPQI) via induction of cytochrome P450 2E1 (CYP2E1). However, CYP2E1 induction appears to be insufficient to explain the claimed magnitude of the interaction. We assessed the role of selective depletion of liver mitochondrial glutathione (GSH) by chronic ethanol. Rats were fed the Lieber‐DeCarli diet for 10 days or 6 weeks.
Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation
George K. K. Lau, Ming‐Liang He, Daniel Y. T. Fong, Angeline Bartholomeusz, Wing‐yan Au, Albert K. W. Lie, Stephen Locarnini, Raymond Liang – 30 December 2003 – Exacerbation of hepatitis B virus (HBV) is a serious cause of morbidity and mortality in hepatitis B surface antigen (HBsAg)‐positive patients undergoing transplantation. Our aim was to evaluate the effectiveness of lamivudine to prevent hepatitis due to exacerbation of HBV in HBsAg‐positive patients treated with allogeneic hematopoietic cell transplantation.
Inhibitory activity of dioxolane purine analogs on wild‐type and lamivudine‐resistant mutants of hepadnaviruses
Béatrice Seignères, Christian Pichoud, Perrine Martin, Philip Furman, Christian Trépo, Fabien Zoulim – 30 December 2003 – To design combination strategies for chronic hepatitis B therapy, we evaluated in vitro the inhibitory activity of 4 nucleoside analogs, (−)FTC, L‐FMAU, DXG, and DAPD, in comparison with lamivudine (3TC) and PMEA.
Good news for hepatorenal syndrome
Pere Ginès, Mónica Guevara – 30 December 2003
Autoimmunity after liver transplantation
Diego Vergani, Giorgina Mieli‐Vergani – 30 December 2003
Hepatitis C, cryoglobulinemia, and cirrhosis: A meta‐analysis
Zeid Kayali, Victor E. Buckwold, Bridget Zimmerman, Warren N. Schmidt – 30 December 2003 – Approximately 40% of patients with chronic hepatitis C virus (HCV) infection develop detectable serum cryoglobulins or cryoprecipitates (CP), although most do not show clinical or physical signs of syndromic cryoglobulinemia. Although association of HCV with the extrahepatic complications of cryoglobulinemia is widely recognized, the relationship of cryoglobulinemia with liver disease is unclear.
Xanthine oxidase–induced oxidant stress during hepatic ischemia‐reperfusion: Are we coming full circle after 20 years?
Hartmut Jaeschke – 30 December 2003
Proapoptotic and antiproliferative potential of selective cyclooxygenase‐2 inhibitors in human liver tumor cells
Michael André Kern, Dominic Schubert, Dina Sahi, Mirja Mareike Schöneweiß, Ilona Moll, Anke Maria Haugg, Hans Peter Dienes, Kai Breuhahn, Peter Schirmacher – 30 December 2003 – Recent studies have shown increased levels of cyclooxygenase‐2 (COX‐2) in a variety of human malignancies, including hepatocellular carcinoma (HCC), but so far it is unknown whether COX‐2 contributes to the malignant growth and whether inhibition of COX‐2 function modifies the malignant potential of liver tumors.